<!DOCTYPE html>

<html lang="en" xml:lang="en">

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />

<meta name="viewport" content="width=device-width, initial-scale=1" />



<title>Main Vignette</title>

<script>// Pandoc 2.9 adds attributes on both header and div. We remove the former (to
// be compatible with the behavior of Pandoc < 2.8).
document.addEventListener('DOMContentLoaded', function(e) {
  var hs = document.querySelectorAll("div.section[class*='level'] > :first-child");
  var i, h, a;
  for (i = 0; i < hs.length; i++) {
    h = hs[i];
    if (!/^h[1-6]$/i.test(h.tagName)) continue;  // it should be a header h1-h6
    a = h.attributes;
    while (a.length > 0) h.removeAttribute(a[0].name);
  }
});
</script>

<style type="text/css">
code{white-space: pre-wrap;}
span.smallcaps{font-variant: small-caps;}
span.underline{text-decoration: underline;}
div.column{display: inline-block; vertical-align: top; width: 50%;}
div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
ul.task-list{list-style: none;}
</style>



<style type="text/css">
code {
white-space: pre;
}
.sourceCode {
overflow: visible;
}
</style>
<style type="text/css" data-origin="pandoc">
pre > code.sourceCode { white-space: pre; position: relative; }
pre > code.sourceCode > span { display: inline-block; line-height: 1.25; }
pre > code.sourceCode > span:empty { height: 1.2em; }
.sourceCode { overflow: visible; }
code.sourceCode > span { color: inherit; text-decoration: inherit; }
div.sourceCode { margin: 1em 0; }
pre.sourceCode { margin: 0; }
@media screen {
div.sourceCode { overflow: auto; }
}
@media print {
pre > code.sourceCode { white-space: pre-wrap; }
pre > code.sourceCode > span { text-indent: -5em; padding-left: 5em; }
}
pre.numberSource code
{ counter-reset: source-line 0; }
pre.numberSource code > span
{ position: relative; left: -4em; counter-increment: source-line; }
pre.numberSource code > span > a:first-child::before
{ content: counter(source-line);
position: relative; left: -1em; text-align: right; vertical-align: baseline;
border: none; display: inline-block;
-webkit-touch-callout: none; -webkit-user-select: none;
-khtml-user-select: none; -moz-user-select: none;
-ms-user-select: none; user-select: none;
padding: 0 4px; width: 4em;
color: #aaaaaa;
}
pre.numberSource { margin-left: 3em; border-left: 1px solid #aaaaaa; padding-left: 4px; }
div.sourceCode
{ }
@media screen {
pre > code.sourceCode > span > a:first-child::before { text-decoration: underline; }
}
code span.al { color: #ff0000; font-weight: bold; } 
code span.an { color: #60a0b0; font-weight: bold; font-style: italic; } 
code span.at { color: #7d9029; } 
code span.bn { color: #40a070; } 
code span.bu { color: #008000; } 
code span.cf { color: #007020; font-weight: bold; } 
code span.ch { color: #4070a0; } 
code span.cn { color: #880000; } 
code span.co { color: #60a0b0; font-style: italic; } 
code span.cv { color: #60a0b0; font-weight: bold; font-style: italic; } 
code span.do { color: #ba2121; font-style: italic; } 
code span.dt { color: #902000; } 
code span.dv { color: #40a070; } 
code span.er { color: #ff0000; font-weight: bold; } 
code span.ex { } 
code span.fl { color: #40a070; } 
code span.fu { color: #06287e; } 
code span.im { color: #008000; font-weight: bold; } 
code span.in { color: #60a0b0; font-weight: bold; font-style: italic; } 
code span.kw { color: #007020; font-weight: bold; } 
code span.op { color: #666666; } 
code span.ot { color: #007020; } 
code span.pp { color: #bc7a00; } 
code span.sc { color: #4070a0; } 
code span.ss { color: #bb6688; } 
code span.st { color: #4070a0; } 
code span.va { color: #19177c; } 
code span.vs { color: #4070a0; } 
code span.wa { color: #60a0b0; font-weight: bold; font-style: italic; } 
</style>
<script>
// apply pandoc div.sourceCode style to pre.sourceCode instead
(function() {
  var sheets = document.styleSheets;
  for (var i = 0; i < sheets.length; i++) {
    if (sheets[i].ownerNode.dataset["origin"] !== "pandoc") continue;
    try { var rules = sheets[i].cssRules; } catch (e) { continue; }
    var j = 0;
    while (j < rules.length) {
      var rule = rules[j];
      // check if there is a div.sourceCode rule
      if (rule.type !== rule.STYLE_RULE || rule.selectorText !== "div.sourceCode") {
        j++;
        continue;
      }
      var style = rule.style.cssText;
      // check if color or background-color is set
      if (rule.style.color === '' && rule.style.backgroundColor === '') {
        j++;
        continue;
      }
      // replace div.sourceCode by a pre.sourceCode rule
      sheets[i].deleteRule(j);
      sheets[i].insertRule('pre.sourceCode{' + style + '}', j);
    }
  }
})();
</script>




<style type="text/css">body{background-color:#fff;margin:1em auto;max-width:700px;overflow:visible;padding-left:2em;padding-right:2em;font-size:14px;line-height:1.35;hyphens:auto;font-family:"Open Sans","Helvetica Neue",Helvetica,Arial,sans-serif}#header{text-align:center}#TOC{clear:both;margin:0 3em;padding:4px;width:auto;border:1px solid #ccc;border-radius:5px;background-color:#fbfbfb;font-size:13px;line-height:1.2em}#TOC .toctitle{font-weight:bold;font-size:15px;margin-left:5px}#TOC ul{padding-left:40px;margin:5px auto 5px -1.5em}#TOC ul ul{margin-left:-2em}#TOC li{list-style-type:none;line-height:16px}table{margin:1em auto;border-width:1px;border-color:#ddd;border-style:outset;border-collapse:collapse}table th{border-width:2px;padding:5px;border-style:inset}table td{border-width:1px;border-style:inset;line-height:18px;padding:5px 5px}table,table th,table td{border-left-style:none;border-right-style:none}table thead, table .even{background-color:#f7f7f7}p{margin:0.5em 0}sup,sub{position:relative;vertical-align:baseline;top:-0.4em}sub{top:0.4em}blockquote{background-color:#fffff6;padding:0.25em 0.75em}hr{border-style:solid;border:none;border-top:1px solid #777;margin:28px 0}dl{margin-left:0}dl dd{margin-bottom:13px;margin-left:13px}dl dt{font-weight:700}ul{margin-top:0}ul li{list-style:circle outside}ul ul{margin-bottom:0}.hl{background-color:#FFFF99}pre, code{background-color:#f7f7f7;border-radius:3px;color:#333;white-space:pre-wrap}pre{border-radius:3px;margin:5px 0 10px 0;padding:10px}pre:not([class]){background-color:#f7f7f7}code{font-size:85%;font-family:Consolas,Monaco,'Lucida Console','Courier New','Courier',monospace}p > code,li > code{padding:2px 0}figure,.caption{text-align:center}img{display:block;margin:0 auto 0 auto;background-color:#FFF;padding:2px;border-radius:5px;border:1px solid #CCC}h1{margin-top:0;padding-top:10px;padding-bottom:4px;;line-height:30px;letter-spacing:.5px;border-bottom:3px solid #f7f7f7;font-size:175%;hyphens:none}.title{margin-top:1.5em}h2{border-bottom:2px solid #f7f7f7;padding-top:10px;padding-bottom:2px;font-size:145%}h3{border-bottom:1px solid #f7f7f7;padding-top:10px;font-size:120%}h4{margin-left:8px;font-size:110%}.author{font-size:91%;margin-left:0;margin-bottom:0;font-style:normal}h5, h6{border-bottom:1px solid #ccc;font-size:105%}a{color:#0033dd;text-decoration:none}a:hover{color:#6666ff}a:visited{color:#800080}a:visited:hover{color:#BB00BB}a[href^="http:"]{color:#696969;border-bottom:1px dotted #000}a[href^="https:"]{border-bottom:1px dotted #000;color:#696969}code > .kw{color:#555;font-weight:700} code > .dt{color:#902000} code > .dv{color:#40a070} code > .bn{color:#d14} code > .fl{color:#d14} code > .ch{color:#d14} code > .st{color:#d14} code > .co{color:#888888;font-style:italic} code > .ot{color:#007020} code > .al{color:#f00;font-weight:700} code > .fu{color:#900;font-weight:700}  code > .er{color:#a61717;background-color:#e3d2d2} .top{display:inline;position:fixed;bottom:0;right:0;padding:0;font-size:108px}.top img{border:none}a.toplink:link{background-image:url(data:image/png;base64,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);background-repeat:no-repeat;text-decoration:none;background-color:transparent;opacity:.6;filter:alpha(opacity=60);background-position:bottom 7px right;background-size:contain}a.toplink:hover,a.toplink:active{text-decoration:none;background-color:transparent;opacity:.4;filter:alpha(opacity=40);background-position:bottom 7px right;background-size:contain}code span.co{font-style:normal}#nav{position:absolute;top:0;float:left;background-color:#084262;border:none}#nav ul{width:100%;list-style-type:none;text-align:center;color:#fff;font-size:.75em;letter-spacing:2px;font-weight:700;margin:0;padding:0}#nav ul li{display:inline}#nav ul li a,#nav ul li span{color:#fff;background-color:#084262;text-decoration:none;float:left;border-right:1px solid #7394B4;cursor:pointer;padding:.5em 11.5px}#nav ul li a:hover,#nav ul li span{color:#fff;background-color:#257B9D}@media print{#nav,#TOC,#TOC .toctitle,#TOC ul,#TOC ul ul,#TOC li{display:none}}</style>




</head>

<body>




<h1 class="title toc-ignore">Main Vignette</h1>


<div id="TOC">
<ul>
<li><a href="#introduction" id="toc-introduction">Introduction</a></li>
<li><a href="#abbreviations-definition-of-terms-models" id="toc-abbreviations-definition-of-terms-models">Abbreviations,
Definition of Terms, Models</a></li>
<li><a href="#round" id="toc-round">A Note on Rounding</a></li>
<li><a href="#installation" id="toc-installation">Installation</a></li>
<li><a href="#contributors" id="toc-contributors">Contributors</a></li>
<li><a href="#license" id="toc-license">License</a></li>
</ul>
</div>

<div class="top">
<a class="toplink" href="#nav" title="â‡‘ top">Â </a>
</div>
<div id="nav">
<ul>
<li>
<span title="Â» You are here Â«">Main Vignette</span>
</li>
<li>
<a href="ABE.html" title="Average Bioequivalence">ABE</a>
</li>
<li>
<a href="RSABE.html" title="Reference-scaled Average Bioequivalence">RSABE</a>
</li>
<li>
<a href="NI.html">Non-Inferiority</a>
</li>
<li>
<a href="DP.html">Dose-Proportionality</a>
</li>
<li>
<a href="PA.html">Power Analysis</a>
</li>
</ul>
</div>
<div id="introduction" class="section level1">
<h1>Introduction</h1>
<p>The package contains functions to calculate power and estimate sample
size for various study designs used in (not only bio-) equivalence
studies. Power and sample size can be obtained based on different
methods, amongst them prominently the TOST procedure (Two One-Sided
<em>t</em>-Tests).<br />
Version 1.5.6 built 2024-03-18 with R 4.3.3.</p>
<p>For an overview of supported designs, methods, and defaults together
with some basic examples see</p>
<ul>
<li><a href="https://cran.r-project.org/package=PowerTOST/readme/README.html">README</a>
of the released version on CRAN;</li>
<li><a href="https://github.com/Detlew/PowerTOST#readme">README</a> of
the development version on GitHub.<br />
</li>
</ul>
<h3>
Details and examples are accessible via the menu bar on top of the page
and in the
<a href="https://cran.r-project.org/package=PowerTOST/PowerTOST.pdf" title="PDF">online
manual</a> of all functions.
</h3>
</div>
<div id="abbreviations-definition-of-terms-models" class="section level1">
<h1>Abbreviations, Definition of Terms, Models</h1>
<dl>
<dt>2Ã—2Ã—2</dt>
<dd>
Crossover design with 2 treatments, 2 sequences, and 2 periods. In the
literature also TR|RT or AB|AB. In the functions <code>2x2x2</code> or
<code>2x2</code> for short.
</dd>
<dt>2x2x3</dt>
<dd>
Full replicate designs with 2 treatments, 2 sequences, and 3 periods
(TRT|RTR or TRR|RTT). Both T and R are administered twice to Â½ of the
subjects.
</dd>
<dt>2x2x4</dt>
<dd>
Full replicate designs with 2 treatments, 2 sequences, and 4 periods
(TRTR|RTRT, TRRT|RTTR, or TTRR|RRTT). Both T and R are administered
twice to Â½ of the subjects.
</dd>
<dt>2Ã—3Ã—3</dt>
<dd>
Partial (or semi-) replicate design with 2 treatments, 3 sequences, and
3 periods (TRR|RTR|RRT or TRR|RTR). R is administered to all subjects
twice and T once. The former is popular (though not optimal) and the
latter (<span title="also known as">a.k.a.</span> extra-reference
design) not optimal because it is biased in the presence of period
effects.
</dd>
<dt>2Ã—4Ã—2</dt>
<dd>
Full replicate design with 2 treatments, 4 sequences, and 2 periods
(TR|RT|TT|RR, Balaamâ€™s design). Not optimal due to poor power
characteristics.
</dd>
<dt>2Ã—4Ã—4</dt>
<dd>
Full replicate designs with 2 treatments, 4 sequences, and 4 periods
(TRTR|RTRT|TRRT|RTTR or TRTR|RTRT|TTRR|RRTT).
</dd>
<dt>3Ã—3, 3Ã—6Ã—3</dt>
<dd>
Higher-order crossover designs with 3 treatments, 3 or 6 sequences, and
3 periods (Latin Square ABC|BCA|CAB or the Williamsâ€™ design
ABC|ACB|BAC|BCA|CAB|CBA). In the functions <code>3x3</code> and
<code>3x6x3</code>. Both have the same degrees of freedom
(2<em>n</em>â€“4) in the conventional approach and therefore, require the
same number of subjects.
</dd>
<dt>4Ã—4</dt>
<dd>
Higher-order crossover design with 4 treatments, 4 sequences, and 4
periods (Latin Square ABCD|BCDA|CDAB|DABC or any of the six Williamsâ€™
designs ADBC|BACD|CBDA|DCAB, ADCB|BCDA|CABD|DBAC, ACDB|BDCA|CBAD|DABC,
ACBD|BADC|CDAB|DBCA, ABDC|BCAD|CDBA|DACB, ABCD|BDAC|CADB|DCBA).
</dd>
<dt><span id="abe">ABE</span></dt>
<dd>
Average Bioequivalence with <em>fixed</em> limits based on a clinically
not relevant difference <span class="math inline">\(\small{\Delta}\)</span>. The common <span class="math inline">\(\small{\Delta}\)</span> 0.20 leads to <span class="math inline">\(\small{\theta_1=1-\Delta,\:\theta_2=1/(1-\Delta)}\)</span>
or 80.00â€“125.00%. For <a href="#ntid">NTIDs</a> (<span title="European Medicines Agency">EMA</span> and other jurisdicions)
<span class="math inline">\(\small{\Delta}\)</span> 0.10
(90.00â€“111.11%). For highly variable <em>C</em><sub>max</sub> (Russian
Federation, South Africa) <span class="math inline">\(\small{\Delta}\)</span> 0.25 (75.00â€“133.33%).<span class="math display">\[H_0:\;\frac{\mu_\textrm{T}}{\mu_\textrm{R}}\ni\left\{\theta_1,\,\theta_2\right\}\;vs\;H_1:\;\theta_1&lt;\frac{\mu_\textrm{T}}{\mu_\textrm{R}}&lt;\theta_2\]</span>
</dd>
<dt><span id="abel">ABEL</span></dt>
<dd>
Average Bioequivalence with <em>expanding</em> limits (see also
<strong><em><a href="#LU">L, U</a></em></strong>). Same model like for
<a href="#abe">ABE</a> but <span class="math inline">\(\small{\theta_1,\theta_2}\)</span> are based on
the <em>CV</em><sub>wR</sub> observed in the study.
</dd>
<dt><span class="math inline">\(\alpha\)</span></dt>
<dd>
Nominal level of the test. In tests for equivalence commonly 0.05
(except for the ratio of two means with normality on original scale
based on Fiellerâ€™s (â€˜fiducialâ€™) confidence interval in function
<code>sampleN.RatioF()</code> and for non-inferiority/-superiority in
function <code>sampleN.noninf()</code>, where it is 0.025). In the
functions <code>alpha</code>.
</dd>
<dt><span class="math inline">\(\beta\)</span></dt>
<dd>
Probability that the Null-hypothesis of inequivalence is <em>falsely
not</em> rejected. Also the typeÂ II error or producerâ€™s risk, where
<span class="math inline">\(\small{\beta=1-\pi}\)</span>.
</dd>
<dt><span class="math inline">\(\beta_0\)</span></dt>
<dd>
Assumed or true slope of the (linearized) power model of
dose-proportionality <span class="math inline">\(\small{x=\alpha\cdot
dose^{\,\beta},\:\log_{e}x=\alpha+\beta\cdot \log_{e}dose}\)</span>.
Argument <code>beta0</code>.
</dd>
<dt><em>CV</em></dt>
<dd>
<dl>
<dt>Coefficient of variation</dt>
<dd>
Calculated from the residual error of the model of log-transformed data
as <span class="math inline">\(\small{CV=\sqrt{\exp
(\sigma^2)+1}}\)</span>.
<ul>
<li>
In crossover designs the within- (intra-) subject CV. Argument
<code>CV</code>.
</li>
<li>
In parallel designs the total (pooled) CV. Argument <code>CV</code>.
</li>
<li>
In replicate designs the intra-subject CV (assuming homoscedasticity,
argument <code>CV</code>). If heteroÂ­scedasticity is assumed,
<code>CV</code> has to given as a vector with two elements
<code>CVÂ =Â c(x,Â y)</code>, where <code>CV[1]</code> is
<a href="#CVwT">CV<sub>wT</sub></a> and <code>CV[2]</code> is
<a href="#CVwR">CV<sub>wR</sub></a>.
</li>
</ul>
</dd>
</dl>
</dd>
<dt><em>CV</em><sub>b</sub></dt>
<dd>
Between- (inter-) subject coefficient of variation. Argument
<code>CVb</code> is required in function <code>sampleN.RatioF()</code>
and in function <code>sampleN.dp()</code> if <code>designÂ =Â &quot;IBD&quot;</code>
(incomplete block design).
</dd>
<dt><span id="CVcap">CV<sub>cap</sub></span></dt>
<dd>
Upper cap in <a href="#abel">ABEL</a>. If
<a href="#CVwR">CV<sub>wR</sub></a> &gt; CV<sub>cap</sub>, expanding is
based on CV<sub>cap</sub> (and not on
<a href="#CVwR">CV<sub>wR</sub></a>). In all jurisdictions 50%, except
for Health Canada, where CV<sub>cap</sub> â‰ˆ57.4%.
</dd>
<dt><em>CV</em><sub>switch</sub></dt>
<dd>
Switching coefficient of variation in reference-scaling. Only above this
value reference-scaling is acceptable. For highly variable drugs / drug
products 30% (<em>CV</em><sub>0</sub> 0.30, <em>s</em><sub>0</sub>
0.294).
</dd>
<dt><span id="CVwR"><em>CV</em><sub>wR</sub></span></dt>
<dd>
Within-subject coefficient of variation of R; can be estimated in any
replicate design.
</dd>
<dt><span id="CVwT"><em>CV</em><sub>wT</sub></span></dt>
<dd>
Within-subject coefficient of variation of T; can be estimated only in
full replicate designs.
</dd>
<dt><span id="Delta"><span class="math inline">\(\small{\Delta}\)</span></span></dt>
<dd>
Clinically not relevant difference. Commonly 0.20. For
<a href="#ntid">NTIDs</a> (<span title="European Medicines Agency">EMA</span> and other jurisdictions)
<span class="math inline">\(\small{\Delta}\)</span> 0.10, for
<em>C</em><sub>max</sub> (Russian Federation, South Africa) <span class="math inline">\(\small{\Delta}\)</span> 0.25.
</dd>
<dt><span id="HVDP">HVD(P)</span></dt>
<dd>
Highly variable drug (product); commonly defined with a
<a href="#CVwR">CV<sub>wR</sub></a> of â‰¥30%. HVDs exhibit highly
variable clearances (<a href="#CVwR">CV<sub>wR</sub></a> â‰¥30% if
administered as a solution), whereas HVDPs may additionallyÂ â€“ or
solelyÂ â€“ show highly variable absorption. HVDP(s) generally are ones
with a flat dose-response curve.
</dd>
<dt><span id="k"><em>k</em></span></dt>
<dd>
<dl>
<dt>Regulatory constant <span style="font-weight:normal">(also <span class="math inline">\(\small{\theta_\textrm{s}}\)</span>)</span></dt>
<dd>
<p><strong><a href="#abel">ABEL</a></strong>: Based on the switching
coefficient of variation <span class="math inline">\(\small{CV_0=30\%}\)</span>. <span class="math inline">\(\small{k=\log_{e}1.25/\sqrt{\log_{e}(CV_{0}^{2}+1)}\approx
0.760}\)</span>.</p>
</dd>
<dd>
<strong><a href="#rsabe">RSABE</a></strong>: Based on the switching
standard deviation <span class="math inline">\(\small{s_0=0.25}\)</span>. <span class="math inline">\(\small{k=\log_{e}1.25/0.25\approx
0.8926}\)</span>.
</dd>
</dl>
</dd>
<dt><span id="LU"><em>L</em>, <em>U</em></span></dt>
<dd>
<dl>
<dt>ABEL, RSABE</dt>
<dd>
<strong><a href="#abel">ABEL</a></strong>: Lower and upper expanded
limits.
<ul>
<li>
30% &lt; <a href="#CVwR">CV<sub>wR</sub></a> â‰¤ 50%: Based on <span class="math inline">\(\small{s_\textrm{wR}}\)</span>, where <span class="math inline">\(\small{\left\{ {L,\,U} \right\}= 100\cdot \exp
(\mp 0.760 \cdot {s_\textrm{wR}})}\)</span>
</li>
<li>
<a href="#CVwR">CV<sub>wR</sub></a> &gt;
<a href="#CVcap">CV<sub>cap</sub></a>: Applying <span class="math inline">\(\small{s^*_\textrm{wR}=\sqrt{\log_{e}(CV_\textrm{cap}^{2}+1)}}\)</span>
in the expansion formula: <span class="math inline">\(\small{\left\{
{L,\,U} \right\} = {69.84 - 143.19\%}}\)</span>. All jurisdictions
except Health Canada, where <span class="math inline">\(\small{\left\{
{L,\,U} \right\} = {66.7 - 150.0\%}}\)</span>.
</li>
</ul>
</dd>
<dd>
<strong><a href="#rsabe">RSABE</a></strong>: Lower and upper â€˜implied
limitsâ€™.
<ul>
<li>
If <span class="math inline">\(\small{s_\textrm{wR}\geq 0.294: \left\{
{L,\: U} \right\} = 100\cdot \exp (\mp 0.8926 \cdot
{s_\textrm{wR}})}\)</span>
</li>
</ul>
</dd>
</dl>
</dd>
<dd>
<dl>
<dt>Dose-Proportionality</dt>
<dd>
<p><span class="math inline">\(\small{\left\{ {L,\,U}
\right\}=\left[1+\log_{e}0.80/\log_{e}rd,\:1+\log_{e}1.25/\log_{e}rd
\right]}\)</span></p>
</dd>
</dl>
</dd>
<dt>margin</dt>
<dd>
<dl>
<dt>Non-inferiority/-superiority margin <span style="font-weight:normal">(example for <code>logscale = TRUE</code>
where <small><span class="math inline">\(\theta_0=\mu_\textrm{T}/\mu_\textrm{R}\)</span></small>).</span></dt>
<dd>
<p><strong>Non-inferiority</strong>: If margin &lt;Â 1, <u>higher</u>
responses are are assumed to be better. <span class="math display">\[\small{H_0:\,\theta_0 \leq
\log_{e}\textrm{margin}\:vs\:H_1:\,\theta_0&gt;\log_{e}\textrm{margin}}\]</span></p>
</dd>
<dd>
<strong>Non-superiority</strong>: If margin &gt;Â 1, <u>lower</u>
responses are are assumed to be better. <span class="math display">\[\small{H_0:\,\theta_0 \geq
\log_{e}\textrm{margin}\:vs\:H_1:\,\theta_0&lt;\log_{e}\textrm{margin}}\]</span>
</dd>
</dl>
</dd>
<dt><em>n</em></dt>
<dd>
(Total) number of subjects.
</dd>
<dt><em>n</em><sub>seq</sub></dt>
<dd>
Number of sequences.
</dd>
<dt><span id="ntid">NTID</span></dt>
<dd>
Narrow therapeutic index drug, <em>i.e.</em>, with a steep dose-response
curve. <span title="also known as">A.k.a.</span> NRD (Narrow Range
Drug).
</dd>
<dt><span class="math inline">\(\pi\)</span></dt>
<dd>
Target (or desired) power in study planning. Commonly set to
0.80Â â€“Â 0.90. In the functions <code>targetpower</code>.
</dd>
<dt>R</dt>
<dd>
Reference (treatment, product).
</dd>
<dt><em>rd</em></dt>
<dd>
Ratio of the highest/lowest dose. In the functions <code>rd</code>.
</dd>
<dt><code>robust</code></dt>
<dd>
Selects degrees of freedom according to Sennâ€™s basic estimator, where
<span class="math inline">\(\small{df=n-n_\textrm{seq}}\)</span>.
</dd>
<dt><span id="rsabe">RSABE</span></dt>
<dd>
Reference-scaled Average Bioequivalence (U.S. <span title="Food and Drug Administration">FDA</span>, China <span title="National Medical Products Administration, Center for Drug Evaluation">NMPA-CDE</span>).
Applicable if the intra-subject variability of the reference treatment
<em>s</em><sub>wR</sub> â‰¥0.294
(<a href="#CVwR"><em>CV</em><sub>wR</sub></a> â‰ˆÂ 30%). The linearized
model is <span class="math display">\[\small{H_0:(\mu_\textrm{T}/\mu_\textrm{R})^2-\theta_\textrm{s}\cdot
s_\textrm{wR}^{2}&gt;0\:vs\:H_1:(\mu_\textrm{T}/\mu_\textrm{R})^2-\theta_\textrm{s}\cdot
s_\textrm{wR}^{2}\leq 0}\]</span> See also <a href="#abel">ABEL</a>.
</dd>
<dt><span class="math inline">\(\theta_0\)</span></dt>
<dd>
Assumed or true T/R-ratio (<code>logscale = TRUE</code>) or difference
TÂ â€“Â R (<code>logscale = FALSE</code>). In the functions
<code>theta0</code>.
</dd>
<dt><span id="theta12"><span class="math inline">\(\theta_1,\theta_2\)</span></span></dt>
<dd>
Lower and upper limits of the equivalence range. In the functions
<code>theta1</code> and <code>theta2</code>.
</dd>
<dt><span class="math inline">\(\theta_s\)</span></dt>
<dd>
Regulatory constant in reference-scaling (see also
<strong><em><a href="#k">k</a></em></strong>).
</dd>
<dt>T</dt>
<dd>
Test (treatment, product).
</dd>
<dt>TIE <span style="font-weight:normal">(type I error)</span></dt>
<dd>
Probability that the Null-hypothesis of inequivalence is
<em>falsely</em> rejected (<em>i.e.</em>, equivalence is concluded).
Also the patientâ€™s risk. Can be assessed with the power-functions
setting <code>theta0 = theta2</code> or
<code>theta0 = theta1</code>.<br />Exact, except in reference-scaling
based on simulations (<code>power.scABEL()</code>,
<code>power.RSABE()</code>, <code>power.NTIDFDA()</code>,
<code>power.HVNTID()</code>).
</dd>
</dl>
</div>
<div id="round" class="section level1">
<h1>A Note on Rounding</h1>
<p>In all functions sample sizes are estimated based on equivalence
margins [<a href="#theta12"><span class="math inline">\(\small{\theta_1,\theta_2}\)</span></a>] in full
numeric precision. The widened margins for highly variable
<em>C</em><sub>max</sub> are <span class="math inline">\(\small{\theta_1=0.75,}\)</span> <span class="math inline">\(\small{\theta_2=1/\theta_1=1.\dot{3}}\)</span> and
not the rounded 75.00Â â€“ 133.33% according to the guidelines of the
Russian Federation, the <span title="Eurasian Economic Union">EEU</span>, and the <span title="Gulf Cooperation Council">GCC</span>. If for a
<a href="#ntid" title="Narrow Therapeutic Index Drug">NTID</a>
<code>theta1Â =Â 0.90</code> is specified, <span class="math inline">\(\small{\theta_2=1/\theta_1=1.\dot{1}}\)</span> and
not the rounded 111.11% as in the guidelines. Health Canada requires
rounding to only one decimal place with bioequivalence margins for
<a href="#ntid" title="Narrow Therapeutic Index Drugs">NTIDs</a> of
90.0Â â€“ 112.0%.<br />
Estimated sample sizes are generally not affected orÂ â€“ in
<em>extremely</em> rare casesÂ â€“ conservative.</p>
<p>Example for a
<a href="#HVDP" title="Highly Variable Drug Product">HVDP</a> (<span class="math inline">\(\small{\theta_0}\)</span>Â 0.90, design 2x2x4) and
a <a href="#ntid" title="Narrow Therapeutic Index Drug">NTID</a> (<span class="math inline">\(\small{\theta_0}\)</span>Â 0.975, design
2x2x2):</p>
<pre><code>#     CV     agency method   L       U     n   theta1   theta2  n
#  0.574        EMA   ABEL 69.84% 143.19% 30 0.698368 1.431910 30
#  0.574         HC   ABEL 66.7 % 150.0 % 28 0.666667 1.500000 28
#  0.574 RU/EEU/GGC    ABE 75.00% 133.33% 34 0.750000 1.333333 34
#  0.100        EMA    ABE 90.00% 111.11% 22 0.900000 1.111111 22
#  0.100         HC    ABE 90.0 % 112.0 % 22 0.900000 1.111111 22</code></pre>
</div>
<div id="installation" class="section level1">
<h1>Installation</h1>
<p>You can install the released version of PowerTOST from <a href="https://CRAN.R-project.org">CRAN</a> with â€¦</p>
<div class="sourceCode" id="cb2"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb2-1"><a href="#cb2-1" tabindex="-1"></a>package <span class="ot">&lt;-</span> <span class="st">&quot;PowerTOST&quot;</span></span>
<span id="cb2-2"><a href="#cb2-2" tabindex="-1"></a>inst    <span class="ot">&lt;-</span> package <span class="sc">%in%</span> <span class="fu">installed.packages</span>()</span>
<span id="cb2-3"><a href="#cb2-3" tabindex="-1"></a><span class="cf">if</span> (<span class="fu">length</span>(package[<span class="sc">!</span>inst]) <span class="sc">&gt;</span> <span class="dv">0</span>) <span class="fu">install.packages</span>(package[<span class="sc">!</span>inst])</span></code></pre></div>
<p>â€¦ and the development version from <a href="https://github.com/">GitHub</a> with</p>
<pre><code># install.packages(&quot;remotes&quot;)
remotes::install_github(&quot;Detlew/PowerTOST&quot;)</code></pre>
<p>Skips installation from a github remote if the <a href="https://en.wikipedia.org/wiki/SHA-1">SHA-1</a> has not changed
since last install. Use <code>force = TRUE</code> to force
installation.</p>
</div>
<div id="contributors" class="section level1">
<h1>Contributors</h1>
<ul>
<li>Detlew Labes (author, maintainer)</li>
<li>Helmut SchÃ¼tz (author)</li>
<li>Benjamin Lang (author)</li>
</ul>
</div>
<div id="license" class="section level1">
<h1>License</h1>
<h4 class="author">
<a href="https://cran.r-project.org/web/licenses/GPL-3" title="GNU General Public License, Version 3">GPL-3</a> 2024-03-18
Helmut SchÃ¼tz
</h4>
</div>



<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
